CyberMax: open datasets & AI-agent tool demos
Collection
Free open datasets from SEC, Census, BLS, CISA, ClinicalTrials.gov and Common Crawl, plus live demos of CyberMax AI-agent data tools. • 45 items • Updated
nct_id stringlengths 11 11 | brief_title stringlengths 7 300 | acronym stringlengths 1 14 ⌀ | overall_status stringclasses 14
values | why_stopped_category stringclasses 12
values | study_type stringclasses 3
values | phases stringclasses 8
values | allocation stringclasses 3
values | primary_purpose stringclasses 10
values | masking stringclasses 5
values | enrollment int64 0 189M ⌀ | enrollment_type stringclasses 2
values | start_date stringlengths 7 10 ⌀ | primary_completion_date stringlengths 7 10 ⌀ | completion_date stringlengths 7 10 ⌀ | first_posted stringdate 1999-09-20 00:00:00 2026-09-23 00:00:00 | last_updated stringdate 2005-06-24 00:00:00 2026-09-23 00:00:00 | conditions stringlengths 1 11.9k ⌀ | condition_mesh_terms stringlengths 4 5.33k ⌀ | intervention_types stringlengths 4 81 ⌀ | interventions stringlengths 1 1.63k ⌀ | intervention_mesh_terms stringlengths 3 1.84k ⌀ | lead_sponsor stringlengths 2 147 ⌀ | lead_sponsor_class stringclasses 9
values | collaborators stringlengths 2 1.49k ⌀ | has_results bool 2
classes | countries stringlengths 4 619 ⌀ | site_count int64 0 3.51k | sex stringclasses 3
values | minimum_age stringclasses 336
values | maximum_age stringclasses 506
values | healthy_volunteers bool 2
classes | primary_outcomes stringlengths 1 2.48k ⌀ | secondary_ids stringlengths 1 246 ⌀ | url stringlengths 44 44 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT05604235 | Effectiveness of Oncological Physiotherapy on Painful Shoulder Cervical Ganglion in Head and Neck Cancer | null | COMPLETED | null | INTERVENTIONAL | NA | RANDOMIZED | TREATMENT | TRIPLE | 20 | ACTUAL | 2022-11-15 | 2024-06-15 | 2024-11-15 | 2022-11-03 | 2024-11-20 | Cancer; Shoulder Pain; Rehabilitation | Neoplasms; Shoulder Pain | OTHER | Therapeutic upper limb strength exercise treatment; Treatment with passive and active mobilization of the upper limb. | Therapeutics | University of Alcala | OTHER | null | false | Spain | 3 | ALL | 18 Years | 80 Years | false | Eortc QLQ H&N35 questionnaire | CHUNSC_2021_91 | https://clinicaltrials.gov/study/NCT05604235 |
NCT02755935 | CI532 - Early Experience Study | null | COMPLETED | null | INTERVENTIONAL | NA | NA | TREATMENT | NONE | 24 | ACTUAL | 2016-05 | 2017-06 | 2017-09 | 2016-04-29 | 2018-03-20 | Sensorineural Hearing Loss, Bilateral | Hearing Loss, Sensorineural | DEVICE | Cochlear Nucleus CI532 | null | Cochlear | INDUSTRY | null | true | United States | 6 | ALL | 12 Months | null | true | Speech Understanding (% Correct) on AzBio Sentences in Quiet in the Implanted Ear; Speech Understanding (% Correct) on AzBio Sentences in Noise in the Implanted Ear | CAM5660 | https://clinicaltrials.gov/study/NCT02755935 |
NCT07650435 | Thrombectomy in Pulmonary Embolism | TiPE | RECRUITING | null | OBSERVATIONAL | null | null | null | null | 2,000 | ESTIMATED | 2026-05-11 | 2029-12-11 | 2029-12-11 | 2026-06-16 | 2026-06-25 | Pulmonary Embolism and Thrombosis | Pulmonary Embolism; Thrombosis | null | null | null | University Hospital Plymouth NHS Trust | OTHER | null | false | United Kingdom | 1 | ALL | 18 Years | null | false | LV/RV ratio; Morbidity and mortality | 24RAD100; 362530 | https://clinicaltrials.gov/study/NCT07650435 |
NCT03269435 | Greater Occipital Nerve Block Versus Metoclopramide | null | COMPLETED | null | INTERVENTIONAL | PHASE4 | RANDOMIZED | TREATMENT | QUADRUPLE | 99 | ACTUAL | 2017-11-01 | 2020-03-21 | 2020-03-21 | 2017-08-31 | 2021-09-22 | Migraine | Migraine Disorders | PROCEDURE; DRUG | Greater occipital nerve block with bupivacaine; Metoclopramide | Bupivacaine; Metoclopramide | Montefiore Medical Center | OTHER | null | true | United States | 1 | ALL | 18 Years | null | false | 0-10 Pain Score | 2017-8249 | https://clinicaltrials.gov/study/NCT03269435 |
NCT01318135 | Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in Japan | null | COMPLETED | null | INTERVENTIONAL | PHASE2; PHASE3 | RANDOMIZED | TREATMENT | NONE | 576 | ACTUAL | 2009-01 | 2010-01 | 2010-04 | 2011-03-18 | 2012-08-16 | Type 2 Diabetes Mellitus | Diabetes Mellitus, Type 2; Diabetes Mellitus | DRUG | Alogliptin and glimepiride; Alogliptin and metformin | alogliptin; glimepiride; Metformin | Takeda | INDUSTRY | null | true | null | 0 | ALL | 20 Years | 64 Years | false | Number of Participants With Adverse Events. | SYR-322/OCT-005; JapicCTI-090902; U1111-1119-6196 | https://clinicaltrials.gov/study/NCT01318135 |
NCT05242835 | Management of Sleeve Gastrectomy Failure Using Single-anastomosis Metabolic Surgery | null | RECRUITING | null | INTERVENTIONAL | NA | RANDOMIZED | TREATMENT | QUADRUPLE | 151 | ESTIMATED | 2023-02-03 | 2027-01 | 2027-03 | 2022-02-16 | 2025-12-08 | Obesity; Obesity, Morbid | Obesity; Obesity, Morbid | PROCEDURE | Standard duodenal switch; Single-anastomosis duodenal switch | null | Laval University | OTHER | Institut universitaire de cardiologie et de pneumologie de Québec, University Laval | false | Canada | 1 | ALL | 18 Years | 60 Years | false | Excess weight loss | Second stage SADI | https://clinicaltrials.gov/study/NCT05242835 |
NCT03633435 | Home Hemodialysis Assisted by a Nurse for Arterio-venous Fistula Cannulation | DIADIDEAL | UNKNOWN | null | INTERVENTIONAL | NA | NA | TREATMENT | NONE | 10 | ESTIMATED | 2019-03-21 | 2021-11 | 2022-11 | 2018-08-16 | 2021-02-26 | Hemolysis; Cannulation; Arteriovenous Fistula; Nurse's Role | Hemolysis; Arteriovenous Fistula | PROCEDURE | assisted home hemodialysis patients | null | University Hospital, Caen | OTHER | NxStage Medical | false | France | 1 | ALL | 18 Years | null | false | failure of assisted- HDD | 2018-A00992-53 | https://clinicaltrials.gov/study/NCT03633435 |
NCT05784935 | Intelligent-C Endoscopy Module for Real-time Detection of Colonic Lesions | iIDEAS/RTD | COMPLETED | null | OBSERVATIONAL | null | null | null | null | 380 | ACTUAL | 2023-03-20 | 2023-07-01 | 2023-11-01 | 2023-03-27 | 2025-01-27 | Artificial Intelligence; Colonic Polyp | Colonic Polyps | DEVICE | Real time AI detection model | null | Asian Institute of Gastroenterology, India | OTHER | null | false | India | 1 | ALL | 19 Years | 80 Years | true | Performance of a novel state-of-the-art Artificial Intelligence model (AI-Model) for colorectal lesion detection during routine diagnostic colonoscopy | iIDEAS/RTD | https://clinicaltrials.gov/study/NCT05784935 |
NCT03619135 | Effectiveness of External Vibration for Pain Relief During Intravenous Access in Adult Patients | null | COMPLETED | null | INTERVENTIONAL | NA | RANDOMIZED | TREATMENT | NONE | 100 | ACTUAL | 2016-10-17 | 2017-08-24 | 2017-08-24 | 2018-08-07 | 2019-02-05 | Pain Management; Anxiety | Agnosia; Anxiety Disorders; Pain | DEVICE; OTHER | Buzzy; Placebo | null | null | OTHER | null | true | United States | 1 | ALL | 18 Years | 40 Years | true | Change in Pain; Change in Anxiety | 201601806 | https://clinicaltrials.gov/study/NCT03619135 |
NCT06384235 | Phase II Clinical Study of LTC004 in Patients With mCRC | null | UNKNOWN | null | INTERVENTIONAL | PHASE1; PHASE2 | NON_RANDOMIZED | TREATMENT | NONE | 30 | ESTIMATED | 2024-04-25 | 2025-08-23 | 2025-08-23 | 2024-04-25 | 2024-04-25 | Locally Advanced or Metastatic CRC | null | DRUG | LTC004 | null | Letolab | INDUSTRY | null | false | null | 0 | ALL | 18 Years | 75 Years | false | ORR | LTC004-203 | https://clinicaltrials.gov/study/NCT06384235 |
NCT06189235 | Ultrasonography-guided Real-time Modular Systems for Hand Therapy | null | UNKNOWN | null | INTERVENTIONAL | NA | RANDOMIZED | TREATMENT | SINGLE | 149 | ESTIMATED | 2023-06-28 | 2024-04-26 | 2024-07-31 | 2024-01-03 | 2024-01-03 | Health Adults; Patients With Traumatic Hand Injury | null | OTHER | Biofeedback training | null | National Cheng-Kung University Hospital | OTHER | null | false | Taiwan | 1 | ALL | 20 Years | null | true | Change in tissue characteristics - Ultrasonography platform - Hand Injuries Group (System development) - Baseline; Change from Baseline tissue characteristics at 2-3 days - Ultrasonography platform - Hand Injuries Group (System development) - 2-3 days after baseline; Change from Baseline tissue characteristics at 4-5 d... | B-ER-111-012 | https://clinicaltrials.gov/study/NCT06189235 |
NCT03270735 | A Clinical Study to Evaluate the Efficacy and Safety of Hemocoagulase Injection | null | UNKNOWN | null | INTERVENTIONAL | PHASE4 | RANDOMIZED | TREATMENT | DOUBLE | 100 | ESTIMATED | 2017-06-06 | 2018-06 | 2018-12 | 2017-09-01 | 2017-09-01 | Hemoptysis | Hemoptysis | DRUG | Snake venom thrombin (Treatment); Placebo | Therapeutics | Lee's Pharmaceutical Limited | INDUSTRY | Zhaoke Pharmaceutical (Hefei) Company Limited | false | China | 1 | ALL | 18 Years | 75 Years | false | AEs and SAEs | 2016-ZK-003 | https://clinicaltrials.gov/study/NCT03270735 |
NCT05641935 | Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation | null | RECRUITING | null | INTERVENTIONAL | PHASE2 | NA | DIAGNOSTIC | NONE | 210 | ESTIMATED | 2022-11-03 | 2027-08-31 | 2027-08-31 | 2022-12-08 | 2026-02-17 | Recurrent Renal Cell Carcinoma; Renal Cell Carcinoma | Carcinoma, Renal Cell | DRUG; PROCEDURE; OTHER | Sulfur Hexafluoride Lipid Microspheres; Contrast-Enhanced Ultrasound; Computed Tomography; Magnetic Resonance Imaging; Electronic Health Record Review | Magnetic Resonance Spectroscopy; X-Rays | null | OTHER | National Cancer Institute (NCI) | false | United States | 1 | ALL | 18 Years | null | false | Renal cell carcinoma recurrence | 22F.825; R01CA269750; JT 24546 | https://clinicaltrials.gov/study/NCT05641935 |
NCT02320435 | A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial | null | ACTIVE_NOT_RECRUITING | null | INTERVENTIONAL | PHASE3 | NA | TREATMENT | NONE | 154 | ACTUAL | 2015-02-02 | 2026-12-31 | 2026-12-31 | 2014-12-19 | 2026-08-11 | Solid Tumors | null | DRUG | Pertuzumab; Trastuzumab; Other Combination Anti-Cancer Therapies | pertuzumab; Trastuzumab | Hoffmann-La Roche | INDUSTRY | null | false | Brazil; China; Costa Rica; France; Germany; Italy; Japan; Mexico; Peru; Poland; Portugal; Russia; South Korea; Spain; Ukraine | 62 | ALL | 18 Years | null | false | Progression-Free Survival; Overall Survival; Number of Participants with Adverse Events by Severity, Classified According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03; Number of Participants with Adverse Events Leading to Pertuzumab Discontinuation or Dose Int... | MO29406; 2014-002048-42; 2023-505102-42-00; 2023; 2014 | https://clinicaltrials.gov/study/NCT02320435 |
NCT03975335 | Reducing Behavioral Risk Factors of NCDs: Protocol for a School-based Health Education Program in Bangladesh | null | COMPLETED | null | INTERVENTIONAL | NA | RANDOMIZED | OTHER | SINGLE | 823 | ACTUAL | 2018-05-02 | 2018-08-20 | 2018-08-20 | 2019-06-05 | 2019-06-05 | Non-communicable Disease Risk Factors | Risk-Taking | BEHAVIORAL; OTHER | Health education; Carrier Guidance | null | Chi Research & Infotec Ltd. | OTHER | Directorate General of Health Services | false | Bangladesh | 1 | ALL | 14 Years | 18 Years | true | Change in knowledge; Change in attitude; Change in practice | BSMMU/2018/5958 | https://clinicaltrials.gov/study/NCT03975335 |
NCT07616635 | A Trial of Fosfomycin vs Ciprofloxacin for Febrile Neutropenia (FOVOCIP) | FOVOCIP | COMPLETED | null | INTERVENTIONAL | PHASE3 | RANDOMIZED | PREVENTION | NONE | 177 | ACTUAL | 2022-03-14 | 2024-05-29 | 2024-12-01 | 2026-06-01 | 2026-06-01 | Haematopoietic Stem Cell Transplantation; Acute Leukemia | null | DRUG | Fosfomycin; ciprofloxacin | Fosfomycin; Ciprofloxacin | Fundación para la Investigación Biosanitaria del Principado de Asturias | OTHER | null | false | Spain | 1 | ALL | 18 Years | null | false | Febrile neutropenia | PI21/1590 AES 2021; 2021-000354-25 | https://clinicaltrials.gov/study/NCT07616635 |
NCT01257035 | Predictive Value of 18F-FAZA in Rectum Cancer | FAZA | TERMINATED | low_enrollment | OBSERVATIONAL | null | null | null | null | 21 | ACTUAL | 2010-11 | 2012-02 | 2012-08 | 2010-12-09 | 2013-06-17 | Locally Advanced Rectum Cancer | Rectal Neoplasms | OTHER | 18F-FAZA-PET/CT | null | Vejle Hospital | OTHER | Aarhus University Hospital | false | Denmark | 1 | ALL | 18 Years | null | false | Response to chemoradiotherapy measured by TRG | S-20100054 | https://clinicaltrials.gov/study/NCT01257035 |
NCT05504135 | Implementation of Pre-emptive Pharmacogenomics Testing in Singapore-based Private Hospital Institutions (IMPT Study) | null | COMPLETED | null | OBSERVATIONAL | null | null | null | null | 222 | ACTUAL | 2022-10-03 | 2023-08-31 | 2024-08-31 | 2022-08-17 | 2025-05-30 | Pre-emptive Pharmacogenomics | null | DIAGNOSTIC_TEST | Pharmacogenomics Testing | null | Nalagenetics Pte Ltd | INDUSTRY | null | false | Singapore | 1 | ALL | 21 Years | 65 Years | false | Turnaround time of genotype result, compared to expected; Overall satisfaction of patient; Overall satisfaction of site principal investigators; Overall satisfaction of prescribing physicians; Prevalence of clinically actionable genotypes; Recommendation acceptance rate | SG-RMG-01-20190401 | https://clinicaltrials.gov/study/NCT05504135 |
NCT07391735 | Post-Surgery Wound Healing Tracking With MyHealthPal App | null | RECRUITING | null | INTERVENTIONAL | NA | NON_RANDOMIZED | OTHER | NONE | 150 | ESTIMATED | 2026-03-27 | 2027-01-01 | 2027-12-31 | 2026-02-06 | 2026-08-12 | Wound Infection and Wound Healing | Wound Infection | DEVICE | MyHealthPal App | null | Brigham and Women's Hospital | OTHER | null | false | United States | 1 | ALL | 18 Years | null | false | Imageability; Positive/negative percent agreement; Patient Usage/Data Entry; Clinician Feedback; Safety Risk; Patient Satisfaction (6-Week Point) | 2025P003153 | https://clinicaltrials.gov/study/NCT07391735 |
NCT01539135 | The Influence of Endotracheal Tube Design on Fluid Leakage Into the Lungs During Surgery | null | COMPLETED | null | INTERVENTIONAL | NA | RANDOMIZED | PREVENTION | TRIPLE | 80 | ACTUAL | 2012-04 | 2013-05 | 2013-05 | 2012-02-27 | 2015-08-13 | Respiratory Aspiration | Respiratory Aspiration | DRUG | Methylene Blue | Methylene Blue | Medtronic - MITG | INDUSTRY | null | true | United States | 1 | ALL | 18 Years | null | false | Number of Participants With Dye Leakage | COVAIPR0235 | https://clinicaltrials.gov/study/NCT01539135 |
NCT01235208 | The Effect of the Treatment Program "Dr. Fedon Lindbergs Vektcoach" on Body Weight and Composition and Hormonal Profile | null | COMPLETED | null | INTERVENTIONAL | NA | NA | HEALTH_SERVICES_RESEARCH | NONE | 44 | ACTUAL | 2010-10 | 2012-08 | 2012-08 | 2010-11-05 | 2012-08-15 | Overweight; Obesity; Metabolic Syndrome | Overweight; Obesity; Metabolic Syndrome | OTHER | The "Dr. Fedon Lindbergs Vektcoach" Treatment | null | Eurodiet Scandinavia AS | INDUSTRY | null | false | Norway | 1 | ALL | 18 Years | null | false | Body weight/composition | EDstudy | https://clinicaltrials.gov/study/NCT01235208 |
NCT00873808 | S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307 | null | WITHDRAWN | low_enrollment | OBSERVATIONAL | null | null | null | null | 0 | ACTUAL | 2008-10 | 2010-02 | 2010-02 | 2009-04-02 | 2013-04-10 | Breast Cancer | Breast Neoplasms | DRUG; OTHER; PROCEDURE | clodronate disodium; demeclocycline hydrochloride; ibandronate sodium; tetracycline hydrochloride; zoledronic acid; laboratory biomarker analysis; adjuvant therapy; computed tomography; dual x-ray absorptiometry | Clodronic Acid; Demeclocycline; Ibandronic Acid; Tetracycline; Zoledronic Acid; Chemotherapy, Adjuvant; Absorptiometry, Photon | SWOG Cancer Research Network | NETWORK | National Cancer Institute (NCI) | false | United States | 1 | FEMALE | 18 Years | null | false | Change in bone quality after long-term high-dose bisphosphonates as measured by histomorphometry, mineralization density, micro-computed tomography, and biomechanics of bone biopsy samples | CDR0000614118; S0307A; U10CA032102 | https://clinicaltrials.gov/study/NCT00873808 |
NCT01486108 | Burst Spinal Cord Stimulation for Neuropathic Pain | null | COMPLETED | null | INTERVENTIONAL | NA | RANDOMIZED | TREATMENT | QUADRUPLE | 15 | ACTUAL | 2011-01 | 2011-08 | 2011-09 | 2011-12-06 | 2011-12-06 | Neuropathic Pain | Neuralgia | PROCEDURE | dorsal column stimulator | null | University Hospital, Antwerp | OTHER | null | false | Belgium | 1 | ALL | 18 Years | 75 Years | false | Visual Analogue Scales for pain back, pain limb, pain general and paresthesia | burst spinal cord stimulation | https://clinicaltrials.gov/study/NCT01486108 |
NCT07750808 | ZEPU AI9 Exoskeleton Rehabilitation Robot | null | RECRUITING | null | INTERVENTIONAL | NA | RANDOMIZED | TREATMENT | NONE | 36 | ESTIMATED | 2026-08-01 | 2026-10 | 2026-12 | 2026-08-06 | 2026-09-11 | Stroke; Gait Disorders, Neurologic; Spinal Cord Injuries, Incomplete; Postoperative Complication | Stroke; Gait Disorders, Neurologic; Spinal Cord Injuries; Postoperative Complications | DEVICE; BEHAVIORAL | ZEPU-AI9 Lower Limb Exoskeleton Gait Training; Standard-of-Care Rehabilitation | null | Bangladesh Medical University | OTHER | null | false | Bangladesh | 1 | ALL | 18 Years | 60 Years | false | Incidence of Device-Related Adverse Events and Serious Adverse Events; Device Tolerability | PR-1422 | https://clinicaltrials.gov/study/NCT07750808 |
NCT06779708 | The Role of Intraoperative Hepatic Ultrasonography in Gastrointestinal or Pancreatic Neuroendocrine Tumor | ECHO-NET | COMPLETED | null | OBSERVATIONAL | null | null | null | null | 51 | ACTUAL | 2020-10-01 | 2023-12-31 | 2023-12-31 | 2025-01-16 | 2025-01-16 | Neuroendocrine (NE) Tumors; Liver Metastasis | Neoplasms; Neuroendocrine Tumors | null | null | null | Istituto Clinico Humanitas | OTHER | null | false | Italy | 1 | ALL | 18 Years | null | false | Liver metastases | 748/2020 | https://clinicaltrials.gov/study/NCT06779708 |
NCT02762708 | The Effect of Bariatric Surgery on Metabolism, the Metabolome and Microbiome in Patients With Type 2 Diabetes | Microbiome | COMPLETED | null | INTERVENTIONAL | PHASE2 | RANDOMIZED | BASIC_SCIENCE | NONE | 12 | ACTUAL | 2016-03 | 2018-01-06 | 2018-01-06 | 2016-05-05 | 2022-05-03 | Type 2 Diabetes Mellitus; Obesity | Diabetes Mellitus, Type 2; Obesity; Weight Loss | PROCEDURE; BEHAVIORAL; DRUG | Roux-en-Y Gastric Bypass (RYGB); Caloric Restriction; Exendin-9,39; Normal Saline | Gastric Bypass; Bariatric Surgery; Caloric Restriction; Saline Solution | Mayo Clinic | OTHER | null | true | United States | 1 | ALL | 20 Years | 65 Years | true | Fasting Glucose; Peak Glucose; Glucose AUC; Changes in the Gut Microbiome Following RYGB or Caloric Restriction | 15-000179 | https://clinicaltrials.gov/study/NCT02762708 |
NCT01893008 | Preoperative Inspiratory Muscle Training in Esophageal Resection | PREPARE | COMPLETED | null | INTERVENTIONAL | NA | RANDOMIZED | PREVENTION | SINGLE | 245 | ACTUAL | 2013-09 | 2016-07 | 2016-07 | 2013-07-08 | 2017-05-11 | Esophageal Resection Candidates | Esophageal Neoplasms | OTHER | Inspiratory Muscle Training (IMT) | null | UMC Utrecht | OTHER | null | false | Belgium; Finland; Ireland; Netherlands | 9 | ALL | 18 Years | null | false | Pneumonia incidence | NL43194.041.13 | https://clinicaltrials.gov/study/NCT01893008 |
NCT05829408 | KOPPeling: Help From Your Own Circle | null | UNKNOWN | null | INTERVENTIONAL | NA | RANDOMIZED | OTHER | NONE | 128 | ESTIMATED | 2024-04-23 | 2026-08-31 | 2026-08-31 | 2023-04-25 | 2024-08-01 | Children of Parents With a Mental Illness (COPMI) | Mental Disorders | BEHAVIORAL | KOPPeling | null | University Medical Center Groningen | OTHER | null | false | Netherlands | 1 | ALL | null | null | false | Change in Quality of Life (QoL) of COPMI | 10196 | https://clinicaltrials.gov/study/NCT05829408 |
NCT05897008 | The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD, Safety and Immunogenicity | null | COMPLETED | null | INTERVENTIONAL | PHASE1 | RANDOMIZED | TREATMENT | TRIPLE | 114 | ACTUAL | 2022-02-07 | 2022-06-27 | 2022-09-13 | 2023-06-09 | 2023-06-12 | Healthy Volunteers | null | BIOLOGICAL | CMAB007; Xolair | Omalizumab | Taizhou Mabtech Pharmaceutical Co.,Ltd | INDUSTRY | null | false | China | 1 | MALE | 18 Years | 45 Years | true | Area Under the Plasma Concentration-time Curve From Zero (0) Hours Extrapolated to infinite time; Maximum Concentration of Omalizumab | CMAB007-002 | https://clinicaltrials.gov/study/NCT05897008 |
NCT02376608 | Bioavailability of Omega-3 Food Supplement in Healthy Subjects | null | COMPLETED | null | INTERVENTIONAL | PHASE1 | RANDOMIZED | null | NONE | 24 | ACTUAL | 2014-08 | 2014-09 | 2014-09 | 2015-03-03 | 2015-03-03 | Biological Availability | null | DIETARY_SUPPLEMENT | Pronova Pure 150:500 EE EU; Pronovum PRF-037; Pronovum PRF-041; Eskimo-3 | null | Pronova BioPharma | INDUSTRY | null | false | United Kingdom | 1 | null | null | null | true | Area under curve of omega-3 food supplements under light fed conditions in healthy subjects.; Peak plasma concentration of omega-3 food supplements under light fed conditions in healthy subjects. | CTN00714101 | https://clinicaltrials.gov/study/NCT02376608 |
NCT00750308 | Renin Angiotensin Aldosterone System (RAAS) and Fibrinolysis in Humans: ACEi and PE5i | null | COMPLETED | null | INTERVENTIONAL | NA | RANDOMIZED | BASIC_SCIENCE | QUADRUPLE | 27 | ACTUAL | 2006-12 | 2009-01 | 2009-05 | 2008-09-10 | 2014-12-18 | Metabolic Syndrome | Metabolic Syndrome | DRUG | Ramipril; Tadalafil; placebo | Ramipril; Tadalafil | Vanderbilt University | OTHER | National Institutes of Health (NIH) | true | null | 0 | ALL | 18 Years | 70 Years | false | Beta Cell Function; Insulin Sensitivity | 060198 | https://clinicaltrials.gov/study/NCT00750308 |
NCT04574908 | A Pilot Trial of Continuous Portable Postoperative Hemodynamic And Saturation Monitoring On Hospital Wards | null | COMPLETED | null | INTERVENTIONAL | NA | RANDOMIZED | TREATMENT | SINGLE | 879 | ACTUAL | 2020-10-07 | 2021-10-06 | 2021-10-08 | 2020-10-05 | 2024-05-21 | Hemodynamic Instability; Respiratory Complications of Care | null | DEVICE | ViSi device | null | Wake Forest University Health Sciences | OTHER | null | true | United States | 1 | ALL | 18 Years | null | false | Duration of Hypotension in Minutes; Duration of Tachycardia in Minutes; Duration of Hypoxemia (SpO2 < 90%) in Minutes | IRB00063530 | https://clinicaltrials.gov/study/NCT04574908 |
NCT05653908 | REThinkAcademy: Helping Universities to Effectively Care for the Mental Health of College Students in the Digital Age | null | COMPLETED | null | INTERVENTIONAL | NA | NA | SCREENING | NONE | 550 | ACTUAL | 2022-10-20 | 2023-08-31 | 2023-09-30 | 2022-12-16 | 2024-11-01 | Mental Health Issue | null | OTHER | StudentMood | null | Babes-Bolyai University | OTHER | The Executive Agency for Higher Education, Research, Development and Innovation Funding | false | Romania | 1 | ALL | 18 Years | null | true | Rational and irrational beliefs; Changes in rational and irrational beliefs; Fluctuation in rational and irrational beliefs; Mental Health; Changes in Mental Health; Fluctuation in Mental Health; Mood disorders; Changes in mood disorders; Fluctuation in mood disorders; Fluctuation in academic stress | REThin Academy | https://clinicaltrials.gov/study/NCT05653908 |
NCT01113008 | Remote Ischemic Postconditioning in Humans | null | COMPLETED | null | INTERVENTIONAL | NA | RANDOMIZED | null | SINGLE | 266 | ACTUAL | 2009-02 | 2012-02 | 2012-05 | 2010-04-29 | 2015-01-21 | Myocardial Reperfusion Injury | Myocardial Reperfusion Injury | PROCEDURE | Remote ischemic postconditioning; Control group | Control Groups | Hospital Universitario Virgen de la Victoria | OTHER | FUNDACIÓN IMABIS; Red Temática de Investigación Cooperativa en Enfermedades Cardiovasculares | true | Spain | 1 | ALL | 18 Years | null | false | Maximum Increase of Troponin at 24 Hours | PI-0327/2008 | https://clinicaltrials.gov/study/NCT01113008 |
NCT03251508 | Salvage Peanut Oral Immunotherapy Study | SOIT | COMPLETED | null | INTERVENTIONAL | PHASE1; PHASE2 | NA | TREATMENT | NONE | 15 | ACTUAL | 2018-01-03 | 2021-11-23 | 2021-11-23 | 2017-08-16 | 2023-01-30 | Peanut Allergy | Peanut Hypersensitivity | DRUG | Peanut OIT | null | University of North Carolina, Chapel Hill | OTHER | null | true | United States | 1 | ALL | 1 Year | 65 Years | false | Percentage of Participants Experiencing Treatment-emergent Adverse Events During the 2-stage Study Sequence (Safety) | 17-0195 | https://clinicaltrials.gov/study/NCT03251508 |
NCT05435508 | Efficacy of Pain Neuroscience Education and Pre-anesthetic Assessment in Reducing Levels of Anxiety, Stress and Pain in Patients Undergoing Elective Total Abdominal Hysterectomy (ENAH Study) | null | COMPLETED | null | INTERVENTIONAL | NA | RANDOMIZED | TREATMENT | DOUBLE | 62 | ACTUAL | 2024-07-01 | 2025-02-28 | 2025-03-15 | 2022-06-28 | 2026-09-02 | Pain, Chronic; Pain, Postoperative; Anesthesia; Surgery; Anxiety; Stress | Chronic Pain; Pain, Postoperative; Anxiety Disorders | OTHER | Pain Neuroscience Education; Usual care | null | Instituto Neurociencia Del Dolor | OTHER | Hospital Univeristario Benemerita Universidad Autonoma de Puebla | false | Mexico | 1 | FEMALE | 18 Years | 65 Years | false | Change in Visual Analog Scale-Pain (EVA); Change in Perceived Stress Scale - 14 items (PSS-14); Change in Beck Anxiety Inventory (BAI) | INeurocienciaDolor | https://clinicaltrials.gov/study/NCT05435508 |
NCT03793608 | Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy | null | COMPLETED | null | INTERVENTIONAL | PHASE2 | NA | TREATMENT | NONE | 25 | ACTUAL | 2019-03-12 | 2021-02-19 | 2021-05-12 | 2019-01-04 | 2022-05-19 | Peanut Allergy | Peanut Hypersensitivity | DRUG | Dupilumab | dupilumab | Regeneron Pharmaceuticals | INDUSTRY | Sanofi | true | United States; Canada | 9 | ALL | 6 Years | 17 Years | false | Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 444 mg (Cumulative) Peanut Protein at Week 24 | R668-ALG-1702; 2018-003133-15; 2018 | https://clinicaltrials.gov/study/NCT03793608 |
NCT04307108 | Magic Glass Evaluation in People With Stroke | null | COMPLETED | null | INTERVENTIONAL | NA | NA | TREATMENT | NONE | 111 | ACTUAL | 2018-11-11 | 2020-03-30 | 2020-06-10 | 2020-03-13 | 2026-08-18 | Stroke | Stroke | DEVICE | Magic Glass | null | University of Ulster | OTHER | Western Health and Social Care Trust; Southern Health and Social Care Trust | false | Italy; United Kingdom | 3 | ALL | 18 Years | null | false | the usability of the intervention;; the usability of the intervention; the acceptability of the intervention; the process requirements for the new care pathway;; the resource requirements for the new care pathway;; the intensity in Rehabilitation Therapy; the duration in Rehabilitation Therapy | 18/NI/0080 | https://clinicaltrials.gov/study/NCT04307108 |
NCT03525808 | AXIOS Lumen Apposing Metal Stent for Walled Off Necrosis Drainage IDE Study | null | COMPLETED | null | INTERVENTIONAL | NA | NA | TREATMENT | NONE | 40 | ACTUAL | 2018-09-05 | 2020-03-31 | 2020-10-02 | 2018-05-16 | 2021-12-20 | Walled Off Pancreatic Necrosis | Pancreatitis, Acute Necrotizing | DEVICE | AXIOS | null | Boston Scientific Corporation | INDUSTRY | null | true | United States | 5 | ALL | 22 Years | 75 Years | false | Number of Participants With Resolution of WON With Endoscopic Drainage; AXIOS Stent Related or WON Drainage Procedure Related Serious Adverse Events | E7116 | https://clinicaltrials.gov/study/NCT03525808 |
NCT04287608 | Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis | null | COMPLETED | null | OBSERVATIONAL | null | null | null | null | 50 | ACTUAL | 2021-03-10 | 2023-03-29 | 2023-03-29 | 2020-02-27 | 2023-04-28 | Conjunctivitis; Atopic Dermatitis | Conjunctivitis; Dermatitis, Atopic | DRUG | dupilumab | dupilumab | Regeneron Pharmaceuticals | INDUSTRY | Sanofi | false | United States | 15 | ALL | 18 Years | 65 Years | false | Baseline Ophthalmologist Diagnosis; Proportion of patients in each category of ophthalmologist diagnoses; Proportion of patients with symptoms; Proportion of patients with morphological features; Proportion of conjunctivitis events by severity; Duration of conjunctivitis event(s) in patients whose conjunctivitis resolv... | R668-AD-1884 | https://clinicaltrials.gov/study/NCT04287608 |
NCT02301208 | Weekly Cisplatin or Nedaplatin Concurrent With Intensity-modulated Radiation Therapy in Nasopharyngeal Carcinoma | NPC-RCT-WCRT | UNKNOWN | null | INTERVENTIONAL | PHASE3 | RANDOMIZED | TREATMENT | NONE | 120 | ESTIMATED | 2014-12 | 2016-12 | null | 2014-11-25 | 2014-12-08 | Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | DRUG | Nedaplatin; Cisplatin | nedaplatin; Cisplatin | null | OTHER | null | false | null | 0 | ALL | 18 Years | 70 Years | false | Response rate; Progress-free survival | JiangsuCIH | https://clinicaltrials.gov/study/NCT02301208 |
NCT00585208 | Add-On Ramelteon in Bipolar I Disorder With Clinically Significant Sleep Disturbance | null | TERMINATED | business_decision | INTERVENTIONAL | PHASE3 | RANDOMIZED | TREATMENT | QUADRUPLE | 21 | ACTUAL | 2007-12 | 2010-09 | 2010-12 | 2008-01-03 | 2013-05-10 | Insomnia; Bipolar Disorder | Sleep Initiation and Maintenance Disorders; Bipolar Disorder; Parasomnias | DRUG | Ramelteon; Placebo | ramelteon | Lindner Center of HOPE | OTHER | Takeda; University of Cincinnati | false | United States | 1 | ALL | 18 Years | 65 Years | false | Pittsburgh Sleep Quality Index (PSQI); Pittsburgh Insomnia Rating Scale (PIRS) | 07-11-06-04 | https://clinicaltrials.gov/study/NCT00585208 |
NCT02806908 | Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in Narcolepsy | null | COMPLETED | null | INTERVENTIONAL | PHASE2 | RANDOMIZED | TREATMENT | DOUBLE | 24 | ACTUAL | 2016-06 | 2019-05-19 | 2019-05-19 | 2016-06-21 | 2021-01-13 | Narcolepsy; Excessive Sleepiness | Narcolepsy; Disorders of Excessive Somnolence | DRUG | JZP-110; Placebo | solriamfetol | Jazz Pharmaceuticals | INDUSTRY | null | true | Netherlands | 1 | ALL | 21 Years | 65 Years | false | Standard Deviation of Lateral Position (SDLP) at 2 Hours Post-dose (Approximately at Tmax) | 15-005 | https://clinicaltrials.gov/study/NCT02806908 |
NCT06992908 | Reliability of Artificial Intelligence for Treatment Decision for Adult Skeletal Open Bite Patients | AIASOBP | COMPLETED | null | OBSERVATIONAL | null | null | null | null | 53 | ACTUAL | 2024-05-12 | 2025-01-15 | 2025-03-15 | 2025-05-28 | 2025-05-28 | Openbite; Artifical Intelligence | Open Bite | null | null | null | Cairo University | OTHER | null | false | Egypt | 1 | ALL | 18 Years | null | false | accuracy of diagnostic test | Adult skeletal open bite cases; Self-funded by me. | https://clinicaltrials.gov/study/NCT06992908 |
NCT07635108 | MR-guided Single-fraction SBRT for Nodal Oligorecurrent Prostate Cancer (PINPOINT) | PINPOINT | NOT_YET_RECRUITING | null | INTERVENTIONAL | NA | NA | TREATMENT | NONE | 48 | ESTIMATED | 2026-06-01 | 2030-04 | 2035-09 | 2026-06-09 | 2026-06-15 | Prostate Cancer; Oligo-metastatic Prostate Carcinoma; Oligometastatic Cancer; Nodal Oligorecurrent Prostate Cancer | Prostatic Neoplasms; Lymphatic Metastasis | RADIATION | Single-fraction SBRT | null | Odense University Hospital | OTHER | Danish Cancer Society | false | Denmark | 1 | MALE | 18 Years | null | false | Number of Participants with cumulative CTCAE v5.0 grade ≥4 treatment-related adverse events | OP-2499; S-20250058 | https://clinicaltrials.gov/study/NCT07635108 |
NCT00226408 | Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon | null | UNKNOWN | null | INTERVENTIONAL | PHASE3 | RANDOMIZED | TREATMENT | NONE | 600 | null | 2003-11 | null | 2005-09 | 2005-09-27 | 2006-06-21 | Adjuvant; Stage III Malignant Melanoma; Interferon Alpha; Therapy | Melanoma | DRUG | Interferon-alpha-2b | Introns | Dermatologic Cooperative Oncology Group | OTHER | null | false | Germany | 13 | ALL | 18 Years | 70 Years | false | distant metastasis free survival/(DMFI ) | MM-ADJ-5 | https://clinicaltrials.gov/study/NCT00226408 |
NCT05172908 | The Effect of Dexamethasone on Rebound Pain in Patients Receiving Ilioinguinal and Iliohypogastric Nerve Block | null | COMPLETED | null | INTERVENTIONAL | NA | RANDOMIZED | TREATMENT | QUADRUPLE | 60 | ACTUAL | 2022-01-06 | 2023-04-15 | 2023-05-15 | 2021-12-29 | 2023-05-16 | Inguinal Hernia | Hernia, Inguinal | DRUG | Dexamethasone; Saline | Dexamethasone; Sodium Chloride | Karaman Training and Research Hospital | OTHER | null | false | Turkey (Türkiye) | 1 | MALE | 18 Years | null | false | Modified Rebound Pain Score; Analgesic consumption | 08-2021/11 | https://clinicaltrials.gov/study/NCT05172908 |
NCT04636008 | Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer | null | UNKNOWN | null | INTERVENTIONAL | PHASE1; PHASE2 | NA | TREATMENT | NONE | 20 | ESTIMATED | 2020-08-14 | 2024-12 | 2024-12 | 2020-11-19 | 2024-08-06 | Anti-PD-1 Antibody; Radiotherapy; Rectal Cancer; MSI-H; Mmr Deficiency | Rectal Neoplasms; Turcot syndrome | DRUG; RADIATION | Sintilimab; Hypofractionated Radiotherapy | sintilimab; Radiation Dose Hypofractionation | West China Hospital | OTHER | First Affiliated Hospital of Chongqing Medical University; Yunnan Cancer Hospital; Sichuan Cancer Hospital and Research Institute; Chengdu Third People's Hospital; The Affiliated Hospital Of Southwest Medical University | false | China | 1 | ALL | 18 Years | null | false | Adverse reaction | 201919 | https://clinicaltrials.gov/study/NCT04636008 |
NCT04727008 | CXCR4 Modified Anti-BCMA CAR T Cells for Multiple Myeloma | null | UNKNOWN | null | INTERVENTIONAL | PHASE1 | NA | TREATMENT | NONE | 12 | ESTIMATED | 2022-09-21 | 2025-12-31 | 2025-12-31 | 2021-01-27 | 2023-12-12 | Multiple Myeloma | Multiple Myeloma | BIOLOGICAL | CXCR4 modified anti-BCMA CAR T cells | null | Sichuan University | OTHER | null | false | China | 1 | ALL | 18 Years | 75 Years | false | Dose limiting toxicities (DLT); Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) | MCART-001 | https://clinicaltrials.gov/study/NCT04727008 |
NCT04079608 | Rigorous Evaluation of High School FLASH | null | COMPLETED | null | INTERVENTIONAL | NA | RANDOMIZED | PREVENTION | NONE | 1,597 | ACTUAL | 2016-10-05 | 2019-01-30 | 2019-06-30 | 2019-09-06 | 2019-09-11 | Pregnancy Related; Sexual Behavior; STD | Sexual Behavior; Harm Reduction | BEHAVIORAL | FLASH curriculum; Sexual Health Education for Adolescents | Sex Education | null | OTHER | Public Health Seattle King County | false | United States | 1 | ALL | 14 Years | 18 Years | true | Self-reported rates of vaginal sex; Self-reported rates of vaginal sex without a condom or other birth control | FLASH study | https://clinicaltrials.gov/study/NCT04079608 |
NCT04710108 | Testing Message Modality of Culturally Appropriate Nutrition Communication for Mexican American Women | null | COMPLETED | null | INTERVENTIONAL | NA | RANDOMIZED | PREVENTION | NONE | 129 | ACTUAL | 2020-12-02 | 2021-05-15 | 2021-12-25 | 2021-01-14 | 2022-05-19 | Sugar Sweetened Beverage Consumption; Nutrition; Lifestyle-related Condition; Lifestyle Risk Reduction | Mental Disorders; Risk Reduction Behavior | OTHER | Health Communication | Health Communication | University of California, Merced | OTHER | National Cancer Institute (NCI) | false | United States | 1 | ALL | 18 Years | 29 Years | true | Knowledge; Attitude toward sugary beverage consumption; Subjective norms toward sugary beverage consumption; Self-efficacy toward SSB consumption; Intention to reduce SSB consumption; Media literacy; Public health literacy; Empowerment | K01CA190659-5; K01CA190659 | https://clinicaltrials.gov/study/NCT04710108 |
NCT05747625 | (89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma | null | RECRUITING | null | INTERVENTIONAL | PHASE1 | NA | SUPPORTIVE_CARE | NONE | 60 | ESTIMATED | 2023-05-09 | 2027-02-28 | 2030-03-01 | 2023-02-28 | 2026-05-08 | Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Squamous Cell Carcinoma; Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma of Head and Neck | BIOLOGICAL; DRUG; PROCEDURE; OTHER | Panitumumab; Zirconium Zr 89 Panitumumab; Positron Emission Tomography; Computed Tomography; Electronic Health Record Review | Panitumumab; Magnetic Resonance Spectroscopy | null | OTHER | Vanderbilt-Ingram Cancer Center; Vanderbilt University Medical Center | false | United States | 1 | ALL | 19 Years | null | false | Sensitivity of zirconium Zr 89 panitumumab (89Zr-panitumumab; Specificity of 89Zr-panitumumab | VICCHN2279; NCI-2023-01365 | https://clinicaltrials.gov/study/NCT05747625 |
NCT01136525 | Bioavailability Study of Valacyclovir HCl Tablets, 1000 mg of Dr. Reddy's Under Fasting Conditions | null | COMPLETED | null | INTERVENTIONAL | PHASE1 | RANDOMIZED | TREATMENT | NONE | 41 | ACTUAL | 2007-02 | 2007-03 | 2007-05 | 2010-06-03 | 2010-06-14 | Healthy | null | DRUG | Valacyclovir Hydrochloride | Valacyclovir | Dr. Reddy's Laboratories Limited | INDUSTRY | null | false | India | 1 | ALL | 18 Years | 45 Years | true | Bioequivalence based on Cmax and AUC parameters | 07-VIN-027 | https://clinicaltrials.gov/study/NCT01136525 |
NCT03306225 | Characterization of Endocarditis to Streptococci and Impact of the CMI on the Future of the Patients | null | COMPLETED | null | OBSERVATIONAL | null | null | null | null | 414 | ACTUAL | 2016-07-08 | 2018-12-31 | 2019-12-31 | 2017-10-10 | 2020-02-05 | Endocarditis, Bacterial | Endocarditis, Bacterial | null | null | null | Fondation Hôpital Saint-Joseph | OTHER | null | false | France | 1 | ALL | 18 Years | null | false | Evaluation of factors associated to the mortality in the patients presenting an endocarditis to streptococci. | ENDOSTREPTO | https://clinicaltrials.gov/study/NCT03306225 |
NCT03085225 | Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas. | TRAMUNE | COMPLETED | null | INTERVENTIONAL | PHASE1 | NA | TREATMENT | NONE | 40 | ACTUAL | 2017-05-05 | 2020-11-19 | 2022-01-04 | 2017-03-21 | 2025-09-04 | Ovarian Carcinoma; Soft Tissue Sarcoma | Ovarian Neoplasms; Sarcoma | DRUG | Combination of trabectedin with durvalumab | durvalumab | Institut Bergonié | OTHER | AstraZeneca; PharmaMar | true | France | 2 | ALL | 18 Years | null | false | Dose Escalation Part: Establish the Recommended Phase II Dose (RP2D), the Maximum Tolerated Dose (MTD) Evaluated on the First Cycle (D1 to D21), the Safety Profile, and the Dose Limiting Toxicities (DLT) of Trabectedin Given in Combination With Durvalumab; Expansion Cohorts : Evaluate Preliminary Signs of the Antitumor... | IB2016-02 | https://clinicaltrials.gov/study/NCT03085225 |
NCT06751225 | Evaluation of Wear Experience With a Weekly Replacement Soft Contact Lens in Neophyte Lens Wearers With Astigmatism | null | COMPLETED | null | INTERVENTIONAL | NA | NA | TREATMENT | NONE | 40 | ACTUAL | 2025-01-21 | 2025-11-04 | 2025-11-04 | 2024-12-27 | 2026-06-04 | Astigmatism Bilateral | null | DEVICE | One week replacement soft contact lenses | null | Ohio State University | OTHER | Alcon Research | true | United States | 1 | ALL | 18 Years | 40 Years | true | Subjective Assessment of Lens Wear Experience | 2024H0379 | https://clinicaltrials.gov/study/NCT06751225 |
NCT05444725 | Investigating Barriers for Decision Making in a Danish Breast Cancer Screening Context | null | COMPLETED | null | INTERVENTIONAL | NA | RANDOMIZED | HEALTH_SERVICES_RESEARCH | NONE | 3,000 | ACTUAL | 2022-06-22 | 2022-09-05 | 2022-09-05 | 2022-07-06 | 2023-05-11 | Breast Cancer Female; Mammography Screening; Decision Making; Information Seeking Behavior | Information Seeking Behavior | OTHER | Stage of Decision Making; Choice framing; Opportunity Framing | null | University of Aarhus | OTHER | null | false | Denmark | 1 | FEMALE | 44 Years | 49 Years | true | Prevalence of women who have made the decision about screening participation prior to screening invitation. | 2016-051-000001, 2563 | https://clinicaltrials.gov/study/NCT05444725 |
NCT05605925 | Ivermectin-artemisinin Combination Therapy for Eradication of Malaria | IVIME | UNKNOWN | null | INTERVENTIONAL | PHASE4 | RANDOMIZED | PREVENTION | NONE | 138 | ESTIMATED | 2022-08-04 | 2022-12-31 | 2022-12-31 | 2022-11-04 | 2022-11-04 | Malaria | Malaria | DRUG | Artemether/lumefantrine; Ivermectin | Artemether, Lumefantrine Drug Combination; Ivermectin | Makerere University | OTHER | null | false | Uganda | 1 | ALL | 18 Years | 65 Years | false | Malaria transmission rates in a household | MAKSHSREC-2021-237 | https://clinicaltrials.gov/study/NCT05605925 |
NCT03532425 | B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults | null | TERMINATED | low_enrollment | INTERVENTIONAL | PHASE4 | RANDOMIZED | TREATMENT | DOUBLE | 28 | ACTUAL | 2018-10-29 | 2020-08-03 | 2020-09-03 | 2018-05-22 | 2022-12-14 | HIV-1-infection | null | DRUG | B/F/TAF; Atripla; B/F/TAF Placebo; Atripla Placebo | bictegravir, emtricitabine, tenofovir alafenamide, drug combination; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | University of Alberta | OTHER | Gilead Sciences; University of British Columbia | true | Canada | 1 | ALL | 21 Years | null | false | Urine Albumin/Creatinine Ratio (UACR) | BFTAF vs Atripla | https://clinicaltrials.gov/study/NCT03532425 |
NCT02563925 | Brain Irradiation and Tremelimumab in Metastatic Breast Cancer | null | COMPLETED | null | INTERVENTIONAL | NA | NA | TREATMENT | NONE | 28 | ACTUAL | 2015-09-18 | 2021-07-14 | 2021-07-14 | 2015-09-30 | 2022-08-03 | Metastatic Breast Cancer | Breast Neoplasms | RADIATION; DRUG | Brain radiotherapy or Stereotactic Radiosurgery; Tremelimumab; HER2 directed therapy; Durvalumab | Radiosurgery; tremelimumab; durvalumab | Memorial Sloan Kettering Cancer Center | OTHER | MedImmune LLC | true | United States | 1 | FEMALE | 18 Years | null | false | Progression Free Survival (irPFS) | 15-038 | https://clinicaltrials.gov/study/NCT02563925 |
NCT00615225 | Brain Death: Inflammatory Response, Apoptosis, and Endotoxin Tolerance | null | COMPLETED | null | OBSERVATIONAL | null | null | null | null | null | null | 2000-01 | 2007-11 | 2007-12 | 2008-02-14 | 2008-02-14 | Brain Death | Brain Death; Inflammation | PROCEDURE | Muscle biopsy | null | Delafontaine Hospital | OTHER | null | false | Belgium; France | 3 | ALL | 18 Years | null | true | null | CCPPRB/114-02; Agence de Biomédecine 2005 | https://clinicaltrials.gov/study/NCT00615225 |
NCT03379025 | Effects of Electronic Cigarettes in Cigarette Smokers With Mild to Moderate COPD | null | WITHDRAWN | never_started | INTERVENTIONAL | NA | RANDOMIZED | OTHER | SINGLE | 0 | ACTUAL | 2019-10 | 2021-04 | 2021-08 | 2017-12-20 | 2019-11-06 | COPD; Tobacco Use | Pulmonary Disease, Chronic Obstructive; Tobacco Use; Vaping | OTHER | Electronic cigarette | Electronic Nicotine Delivery Systems | Massachusetts General Hospital | OTHER | null | false | null | 0 | ALL | 40 Years | 80 Years | false | Change in cigarettes per day | 2017P002418 | https://clinicaltrials.gov/study/NCT03379025 |
NCT01997125 | Reanimation in Tetraplegia | null | COMPLETED | null | INTERVENTIONAL | NA | NA | OTHER | NONE | 1 | ACTUAL | 2013-11 | 2019-06-13 | 2019-06-13 | 2013-11-27 | 2021-08-31 | Spinal Cord Injury (Quadraplegia) | Spinal Cord Injuries; Quadriplegia | DEVICE | Neural Bridge System | null | null | OTHER | null | true | United States | 1 | ALL | 21 Years | 89 Years | false | Number of Participants With Voluntary Movement | 2013H0164 | https://clinicaltrials.gov/study/NCT01997125 |
NCT02687425 | Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous Leukemia | SESPI | UNKNOWN | null | INTERVENTIONAL | PHASE2 | NA | TREATMENT | NONE | 20 | ESTIMATED | 2016-02 | 2016-11 | 2017-06 | 2016-02-22 | 2016-02-22 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | DRUG | Pioglitazone; imatinib mesylate | Pioglitazone; Imatinib Mesylate; Tyrosine Kinase Inhibitors | null | OTHER | null | false | null | 0 | ALL | 18 Years | 65 Years | false | the rate of complete molecular response after the treatment of pioglitazone in combination with imatinib mesylate | CML-201602 | https://clinicaltrials.gov/study/NCT02687425 |
NCT01540825 | First in Man Trial of BI 113608 | null | COMPLETED | null | INTERVENTIONAL | PHASE1 | RANDOMIZED | TREATMENT | DOUBLE | 80 | ACTUAL | 2012-02 | 2012-05 | 2012-05 | 2012-02-29 | 2017-01-20 | Healthy | null | DRUG | BI 113608; Placebo | null | Boehringer Ingelheim | INDUSTRY | null | true | Germany | 1 | MALE | 18 Years | 50 Years | true | Clinically Relevant Abnormalities for Clinical Laboratory Evaluation, Vital Signs, Lung Function, Carbon Monoxide Diffusing Capacity of the Lung, ECG, Physical Examination, Orthostasis Test, Oxygen Saturation or Haemoccult Test; Percentage of Participants With Drug-related Adverse Events; Assessment of Tolerability by ... | 1314.1; 2011-005034-19 | https://clinicaltrials.gov/study/NCT01540825 |
NCT03425825 | Treatment Patterns in Advanced Small Cell Lung Cancer (SCLC) | null | COMPLETED | null | OBSERVATIONAL | null | null | null | null | 764 | ACTUAL | 2016-12-15 | 2019-01-24 | 2019-01-24 | 2018-02-08 | 2022-01-26 | Lung Cancer | Lung Neoplasms; Small Cell Lung Carcinoma | null | null | null | Bristol-Myers Squibb | INDUSTRY | null | false | Spain; United Kingdom | 2 | ALL | 18 Years | null | false | Distribution of Patient Demographic Characteristics; Distribution of Patient Clinical Characteristics in Relapsed/refractory patients receiving second- or later-line treatment; Distribution of Patient Clinical Characteristics in patients with LD-SCLC; Distribution of Patient Clinical Characteristics in patients with ED... | CA209-913 | https://clinicaltrials.gov/study/NCT03425825 |
NCT06107725 | Maimonides Minocycline in Stroke Study | null | TERMINATED | low_enrollment | INTERVENTIONAL | PHASE2; PHASE3 | RANDOMIZED | TREATMENT | SINGLE | 2 | ACTUAL | 2023-11-01 | 2024-05-09 | 2024-05-09 | 2023-10-30 | 2025-12-17 | Stroke, Acute; Ischemic Stroke; Hemorrhagic Stroke; Mortality; Morbidity | Stroke; Ischemic Stroke; Hemorrhagic Stroke; cyclopia sequence | DRUG | Minocycline | Minocycline | Maimonides Medical Center | OTHER | null | true | United States | 1 | ALL | 18 Years | null | false | In-hospital and 30-day Mortality | 2023-05-16-MMC | https://clinicaltrials.gov/study/NCT06107725 |
NCT00600925 | A Study of an Antibiotic Implant in General Surgical Subjects at Higher Risk for Surgical Wound Infection | null | COMPLETED | null | INTERVENTIONAL | PHASE3 | RANDOMIZED | PREVENTION | DOUBLE | 602 | ACTUAL | 2008-01 | 2009-03 | 2010-09 | 2008-01-25 | 2021-09-24 | Colorectal Surgery; Surgical Wound Infection | Surgical Wound Infection | DRUG | gentamicin-collagen sponge dipped in saline | Sodium Chloride | Innocoll | INDUSTRY | Duke University; Premier Research | true | United States | 39 | ALL | 18 Years | null | false | Number of Participants With Surgical Wound Infections From Surgery Through Post-operative Day 60 | INN-SWI-002 | https://clinicaltrials.gov/study/NCT00600925 |
NCT04049825 | A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL | null | COMPLETED | null | INTERVENTIONAL | PHASE1 | NON_RANDOMIZED | TREATMENT | NONE | 36 | ACTUAL | 2019-11-22 | 2025-03-25 | 2026-01-19 | 2019-08-08 | 2026-04-08 | Relapsed or Refractory Diffuse Large B-cell Lymphoma | Recurrence; Lymphoma, Large B-Cell, Diffuse | DRUG | OPB-111077 | null | Otsuka Pharmaceutical Co., Ltd. | INDUSTRY | null | false | Japan | 1 | ALL | 20 Years | 80 Years | false | Dose-limiting toxicity (DLT); Incidence of Adverse events(AEs) | 317-102-00007; jRCT2080224718 | https://clinicaltrials.gov/study/NCT04049825 |
NCT02891525 | The Influence of Sweet Substrates on Hunger, Gastrointestinal Hormones and the Migrating Motor Complex | null | COMPLETED | null | INTERVENTIONAL | NA | RANDOMIZED | BASIC_SCIENCE | DOUBLE | 12 | ACTUAL | 2015-03 | 2016-02 | null | 2016-09-07 | 2016-09-07 | Healthy | null | DIETARY_SUPPLEMENT | 50g glucose; 25g fructose; 220mg acesulfame-K; 250mL tap water | Glucose; Fructose; acetosulfame | Universitaire Ziekenhuizen KU Leuven | OTHER | null | false | null | 0 | ALL | 18 Years | 60 Years | true | Change in gastrointestinal motility measured by antroduodenal high-resolution manometry | GIMotilitySweetTaste | https://clinicaltrials.gov/study/NCT02891525 |
NCT05106725 | Wearable Devices and Biomarkers Project (Healthiomics) | null | UNKNOWN | null | OBSERVATIONAL | null | null | null | null | 3,500 | ESTIMATED | 2021-10-11 | 2025-12-31 | 2025-12-31 | 2021-11-04 | 2024-08-21 | Brain Cancer; Neurological Disorder; Neurological Cancer | Brain Neoplasms; Nervous System Diseases; Central Nervous System Neoplasms | null | null | null | null | OTHER | null | false | United States | 1 | ALL | 18 Years | null | true | Specimen and data storage | CSI-01-0706 | https://clinicaltrials.gov/study/NCT05106725 |
NCT04090125 | Improving Physical Activity and Gait Symmetry After Total Knee Arthroplasty | PAS-TKA | COMPLETED | null | INTERVENTIONAL | NA | RANDOMIZED | TREATMENT | SINGLE | 60 | ACTUAL | 2019-11-08 | 2023-07-26 | 2023-07-26 | 2019-09-16 | 2024-03-05 | Knee Replacement, Total; Knee Arthroplasty, Total | null | BEHAVIORAL | PAS Intervention; Attention Control | null | University of North Carolina, Chapel Hill | OTHER | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | true | United States | 1 | ALL | 18 Years | null | false | Change From Baseline to Month 3 in Objectively Assessed Physical Activity (Accelerometer); Change From Baseline to Month 6 in Objectively Assessed Physical Activity (Accelerometer); Change From Baseline to Month 3 in Peak Joint Load Symmetry During Walking; Change From Baseline to Month 6 in Peak Joint Load Symmetry Du... | 19-0568; R21AR074149-01A1 | https://clinicaltrials.gov/study/NCT04090125 |
NCT02769325 | Atropine in Laparoscopic Gynaecological Surgery | ALGOS | UNKNOWN | null | INTERVENTIONAL | PHASE4 | RANDOMIZED | TREATMENT | QUADRUPLE | 150 | ESTIMATED | 2016-05 | 2017-05 | 2017-08 | 2016-05-11 | 2016-05-11 | Laparoscopic Surgery; Gynecology | Pain, Postoperative | DRUG | Atropine; Placebo; Sevoflurane; sugammadex; Ketorolac; Morphine PCA; rocuronium; propofol | Atropine; Sevoflurane; Sugammadex; Ketorolac; Rocuronium; Propofol | Clinica Santa Maria | OTHER | null | false | Chile | 1 | FEMALE | 18 Years | 65 Years | false | 24 hours morphine consumption | CSM2016001 | https://clinicaltrials.gov/study/NCT02769325 |
NCT05725525 | A Study of Internet Delivered Parent Child Interaction Therapy | AI I-PCIT | COMPLETED | null | INTERVENTIONAL | NA | NA | TREATMENT | NONE | 5 | ACTUAL | 2023-03-02 | 2023-12-01 | 2023-12-01 | 2023-02-13 | 2024-04-01 | Disruptive Behavior | Problem Behavior | BEHAVIORAL | Remote PCIT augmented with wearable devices | Wearable Electronic Devices | Mayo Clinic | OTHER | null | false | United States | 1 | ALL | 3 Years | 99 Years | true | How wearing a Garmin watch will help the remote PCIT clinical outcomes; Number of participants able to wear the Garmin watch throughout remote PCIT; Evaluating parental acceptance of remote PCIT augmented with a Garmin device | 22-009425 | https://clinicaltrials.gov/study/NCT05725525 |
NCT07600125 | Evaluation of Fecal Multi-target Biomarkers in the Screening of Digestive Tract Cancers | null | RECRUITING | null | OBSERVATIONAL | null | null | null | null | 5,000 | ESTIMATED | 2026-08-10 | 2027-12-31 | 2027-12-31 | 2026-05-20 | 2026-08-11 | Gastric Cancer, Colorectal Cancer | Stomach Neoplasms; Colorectal Neoplasms | DIAGNOSTIC_TEST | Qualitative Fecal Immunochemical Test (FIT), quantitative (FIT), and testing for new biomarkers | null | Xijing Hospital | OTHER | null | false | China | 13 | ALL | 18 Years | null | true | Sensitivity and Specificity of Stool-Based Biomarker Testing for Gastrointestinal Cancer Screening | KY20262030-C-1 | https://clinicaltrials.gov/study/NCT07600125 |
NCT06675825 | An Innovative Endoscopic Cap for Dilating Benign Esophageal Strictures in Children | BOUGIE-PED | RECRUITING | null | INTERVENTIONAL | NA | RANDOMIZED | OTHER | SINGLE | 40 | ESTIMATED | 2025-01 | 2026-12 | 2026-12 | 2024-11-05 | 2024-12-11 | Esophageal Stenosis; Esophageal Dilation | Esophageal Stenosis | DEVICE | BougieCap; Savary-Bougie (A) or balloon dilation (B) | null | University Children's Hospital, Zurich | OTHER | null | false | Italy; Switzerland | 3 | ALL | 0 Years | 18 Years | false | Successful dilation | BASEC2023-D0111; SNCTP000005847 | https://clinicaltrials.gov/study/NCT06675825 |
NCT02389725 | The Effect of Two Different Tourniquet Techniques on Peripheral IV Access Success Rates | null | COMPLETED | null | INTERVENTIONAL | NA | RANDOMIZED | BASIC_SCIENCE | SINGLE | 121 | ACTUAL | 2015-04 | 2016-06 | 2016-06 | 2015-03-17 | 2019-05-20 | Tourniquet | null | DEVICE | disposable elastic tourniquet; blood pressure cuff | null | Mayo Clinic | OTHER | null | true | United States | 1 | ALL | 18 Years | null | false | Peripheral IV Access Success Rate | 14-007501 | https://clinicaltrials.gov/study/NCT02389725 |
NCT05929976 | InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort | NICHE | RECRUITING | null | OBSERVATIONAL | null | null | null | null | 4,900 | ESTIMATED | 2022-10-26 | 2029-10-01 | 2029-10-01 | 2023-07-05 | 2025-07-22 | Acute Lymphoblastic Leukemia; Nutrition Aspect of Cancer; Microtia; Genetic Predisposition | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Congenital Microtia; Genetic Predisposition to Disease | OTHER | No intervention | null | Columbia University | OTHER | International Agency for Research on Cancer | false | United States; Brazil; Guatemala; Honduras; India; Tanzania | 8 | ALL | 3 Years | 18 Years | false | Create a prospective multinational biorepository of pediatric specimens (stool, blood) obtained at diagnosis, end of induction, beginning of maintenance, end of treatment, and 1-year after treatment among children/adolescents with ALL.; Collect sociodemographic data at sequential timepoints during treatment for ALL.; C... | AAAU1407 | https://clinicaltrials.gov/study/NCT05929976 |
NCT02699476 | Enhancing Cognitive and Neurobehavioral Functions After Repetitive Traumatic Brain Injuries (rTBI) in Retired NFL Players and Military Veterans. | null | UNKNOWN | null | INTERVENTIONAL | NA | RANDOMIZED | TREATMENT | DOUBLE | 60 | ESTIMATED | 2016-02 | 2017-09 | 2017-12 | 2016-03-04 | 2016-03-04 | Traumatic Brain Injury; Concussion; Mild Cognitive Disorder | Brain Injuries, Traumatic; Brain Concussion; Neurocognitive Disorders | BEHAVIORAL; DEVICE | Psycho-Social Therapy; Cognitive Behavioral Computer Training; Interactive Trainer-Subject Sessions; Active Control Games | null | Brain & Body Health Foundation | OTHER | null | false | United States | 1 | ALL | 25 Years | 55 Years | true | Composite performance score based on battery of neuropsychological tests of working memory, learning, memory, and executive function.; Participant reported outcomes; Working/school status; Exercise-base assessments; Functional assessments | BBHF-001 | https://clinicaltrials.gov/study/NCT02699476 |
NCT05151276 | Mobile Phone-based Video Education on Diabetes | null | COMPLETED | null | INTERVENTIONAL | NA | RANDOMIZED | HEALTH_SERVICES_RESEARCH | NONE | 93 | ACTUAL | 2018-07-01 | 2019-01-31 | 2019-07-01 | 2021-12-09 | 2021-12-09 | Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 2 | BEHAVIORAL | mobile phone-based distance video education group | null | Balikesir University | OTHER | null | false | Turkey (Türkiye) | 1 | ALL | 18 Years | 65 Years | false | The Turkish Multidimensional Diabetes Questionnaire | BAUN"OTEKİR-001 | https://clinicaltrials.gov/study/NCT05151276 |
NCT07760376 | Prevalence, Severity of Dysmenorrhea and Effectiveness of Structured Physiotherapy Interventions Among Doctor of Physical Therapy Students | DPTDYS | COMPLETED | null | INTERVENTIONAL | NA | RANDOMIZED | TREATMENT | SINGLE | 360 | ACTUAL | 2026-02-02 | 2026-06-30 | 2026-06-30 | 2026-08-12 | 2026-08-13 | Primary Dysmenorrhea (PD) | null | BEHAVIORAL; OTHER | Structured Physiotherapy Program; Conventional Treatment for Primary Dysmenorrhea | null | Muhammad Nawaz Sharif University of Agriculture Multan | OTHER | null | false | Pakistan | 1 | FEMALE | 18 Years | 30 Years | false | Pain Intensity (VAS) | MNSUAM/05/28/IAK | https://clinicaltrials.gov/study/NCT07760376 |
NCT03287076 | Trial of EXenatide in Acute Ischaemic Stroke | TEXAIS | UNKNOWN | null | INTERVENTIONAL | PHASE2 | RANDOMIZED | TREATMENT | SINGLE | 350 | ACTUAL | 2017-11-23 | 2021-10-04 | 2021-12-31 | 2017-09-19 | 2021-09-14 | Acute Ischemic Stroke | Ischemic Stroke; Stroke | DRUG | Exenatide Injection | Exenatide | Neuroscience Trials Australia | OTHER | National Health and Medical Research Council, Australia; Monash University | false | Australia; Finland; New Zealand | 15 | ALL | 18 Years | null | false | improved neurological outcome | NTA1127; 2018-004325-88; 2018 | https://clinicaltrials.gov/study/NCT03287076 |
NCT04953676 | A Clinical Trial of the Round-tunnel and Flat-tunnel Technique of ACL Reconstruction | null | UNKNOWN | null | INTERVENTIONAL | NA | RANDOMIZED | TREATMENT | TRIPLE | 144 | ESTIMATED | 2021-09-01 | 2022-09-01 | 2024-09-01 | 2021-07-08 | 2021-07-08 | Anterior Cruciate Ligament Rupture | Anterior Cruciate Ligament Injuries | PROCEDURE | round tunnel technique; flat tunnel technique | null | Peking University Third Hospital | OTHER | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School; Zhengzhou Orthopaedic Hospital; Shenzhen Second People's Hospital | false | null | 0 | ALL | 18 Years | 45 Years | false | KT-2000 | M2020149 | https://clinicaltrials.gov/study/NCT04953676 |
NCT03446976 | CT-P13 (Infliximab) Subcutaneous Administration by Pre-filled Syringe and Auto-injector in Healthy Subjects | null | COMPLETED | null | INTERVENTIONAL | PHASE1 | RANDOMIZED | OTHER | NONE | 218 | ACTUAL | 2018-02-21 | 2018-07-26 | 2018-07-26 | 2018-02-27 | 2019-07-26 | Health, Subjective | null | BIOLOGICAL | CT-P13 SC Auto-injector; CT-P13 SC Pre-filled Syringe | null | Celltrion | INDUSTRY | null | false | United States | 1 | ALL | 18 Years | 55 Years | true | To demonstrate comparable pharmacokinetics (PK) of CT-P13 subcutaneous (SC) administered by auto-injector (AI) versus pre-filled syringe (PFS) in healhty subjects. | CT-P13 1.9; 135134 | https://clinicaltrials.gov/study/NCT03446976 |
NCT06074276 | The Effects of Almond on Facial Skin Collagen and Wrinkles | null | UNKNOWN | null | INTERVENTIONAL | NA | RANDOMIZED | TREATMENT | NONE | 60 | ESTIMATED | 2023-10-04 | 2024-09-30 | 2024-12-31 | 2023-10-10 | 2024-06-18 | Collagen Degeneration; Wrinkle; Pigmentation; Elastic Skin | Ehlers-Danlos Syndrome | OTHER | Food: whole almonds; Food: non-nut snack | null | Integrative Skin Science and Research | INDUSTRY | null | false | United States | 1 | FEMALE | 35 Years | 70 Years | true | Skin collagen and elastin quantification; Facial wrinkles | i23-07_Almond_Collagen | https://clinicaltrials.gov/study/NCT06074276 |
NCT06964776 | A Study of LY4268989 (MORF-057) in Healthy Participants | null | COMPLETED | null | INTERVENTIONAL | PHASE1 | RANDOMIZED | BASIC_SCIENCE | DOUBLE | 144 | ACTUAL | 2025-05-01 | 2026-02-17 | 2026-02-17 | 2025-05-09 | 2026-03-27 | Healthy | null | DRUG | LY4268989; Placebo; Midazolam | Midazolam | Eli Lilly and Company | INDUSTRY | null | false | United States | 1 | ALL | 18 Years | 65 Years | true | Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4268989 (Cohort 1) and (Cohort 5); PK: Area Under the Concentration Curve (AUC) of LY4268989 (Cohort 1) and (Cohort 5); Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (Cohort 1), (Cohort 3), and (Cohort 5);... | 27387; J6E-MC-KWAC; MORF-057 | https://clinicaltrials.gov/study/NCT06964776 |
NCT06088576 | Using a Digital Application for Adolescents in Dropout of Care in Mental Health : Facilitate the Return in Classic Care With Telepsychiatry, Tchats, Forums and a Home Medical Team. | TOGETHER | UNKNOWN | null | INTERVENTIONAL | NA | NA | OTHER | NONE | 50 | ESTIMATED | 2022-06-30 | 2025-06-01 | 2025-06-30 | 2023-10-18 | 2024-03-05 | Mental Health | Psychological Well-Being | OTHER | Together | null | null | OTHER | null | false | France | 1 | ALL | 11 Years | 18 Years | false | The number of connections to the application during the 6 months of support.; The quality of the interaction between the user and the application assessed by AttrakDiff 2. | 2022-A00722-41 | https://clinicaltrials.gov/study/NCT06088576 |
NCT06836076 | Assessment of Depression, Anxiety and ADHD Among Children and Adolescents With Congenital Heart Disease. | Psychiatricy | NOT_YET_RECRUITING | null | OBSERVATIONAL | null | null | null | null | 50 | ESTIMATED | 2025-02 | 2026-02 | 2026-08 | 2025-02-20 | 2025-02-20 | Assessment of Depression, Anxiety and ADHD Among Children and Adolescents With Congenital Heart Disease | Anxiety Disorders; Heart Defects, Congenital; Attention Deficit Disorder with Hyperactivity | null | null | null | Assiut University | OTHER | null | false | null | 0 | ALL | 6 Years | 18 Years | null | • The Child Behaviour Checklist (CBCL/6-18) (arabic version) | Psychiatric disorders children | https://clinicaltrials.gov/study/NCT06836076 |
NCT07207876 | Study of Ceftriaxone and Benzathine Penicillin G During Pregnancy | null | RECRUITING | null | OBSERVATIONAL | null | null | null | null | 110 | ESTIMATED | 2026-02-16 | 2027-01-15 | 2027-09-30 | 2025-10-06 | 2026-08-06 | Pregnancy | Syphilis | DRUG | Ceftriaxon; Benzathine penicillin G | Ceftriaxone; Penicillin G | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | NETWORK | National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Mental Health (NIMH) | false | United States; Puerto Rico | 9 | FEMALE | null | null | false | Geometric mean area under the curve (AUC) during the dosing interval (AUC0-tau) in the first trimester trimester; Geometric mean terminal elimination half-life (t1/2) in the first trimester; Geometric mean trough concentration (Ctrough) in the first trimester; Geometric mean AUC0-tau in the second trimester; Geometric ... | IMPAACT 2044; UM1AI068632; UM1AI068616; UM1AI106716; HHSN275201800001I | https://clinicaltrials.gov/study/NCT07207876 |
NCT01912976 | Study of Methyl Aminolaevulinate Photodynamic Therapy With and Without Er:YAG Laser in Bowen's Disease | null | COMPLETED | null | INTERVENTIONAL | PHASE1 | RANDOMIZED | TREATMENT | DOUBLE | 21 | ACTUAL | 2011-03 | 2012-03 | 2012-03 | 2013-07-31 | 2013-08-01 | Bowen's Disease | Bowen's Disease | DRUG | Er:YAG AFL-PDT; MAL-PDT | null | Dong-A University | OTHER | null | false | South Korea | 1 | ALL | 18 Years | 92 Years | true | Difference the efficacy between Er:YAG AFL-assisted MAL-PDT (Er:YAG AFL-PDT) and standard MAL-PDT. | DAUDerma-01 | https://clinicaltrials.gov/study/NCT01912976 |
NCT01248676 | An Evaluation of the Usability and Usefulness of a Multi-language Online Patient Education Module | null | COMPLETED | null | INTERVENTIONAL | NA | NA | null | NONE | 10 | ESTIMATED | 2010-12 | 2011-04 | 2011-04 | 2010-11-25 | 2011-08-16 | Cancer | Neoplasms | OTHER | Multi-language Online Patient Education Module in addition to standard Patient Teaching | null | Sunnybrook Health Sciences Centre | OTHER | null | false | Canada | 1 | ALL | null | null | false | Patients will be asked to give their rating (Likert scale) on the usefulness of the information on the patient education site with regard to their upcoming radiation simulation and treatment. | Cindy Multi-Language Online | https://clinicaltrials.gov/study/NCT01248676 |
NCT02691676 | Perioperative Fluid Therapy With Balanced Crystalloids | null | COMPLETED | null | INTERVENTIONAL | PHASE3 | RANDOMIZED | TREATMENT | NONE | 112 | ACTUAL | 2014-01 | 2014-12 | 2014-12 | 2016-02-25 | 2017-05-09 | Acid Base Imbalance | Acid-Base Imbalance | DRUG | Plasmalyte; Ringerfundin | Plasmalyte A; Ringerfundin | University Hospital Olomouc | OTHER | null | false | null | 0 | ALL | 18 Years | null | false | Number of participants with significant acid basic disturbances related to balanced alkalizing as compared with a balanced pH-neutral crystalloids. | GV29125 16/14 | https://clinicaltrials.gov/study/NCT02691676 |
NCT06768476 | CART123 + Ruxolitinib in Relapsed/Refractory AML | AML | ACTIVE_NOT_RECRUITING | null | INTERVENTIONAL | PHASE1 | NON_RANDOMIZED | TREATMENT | NONE | 12 | ESTIMATED | 2025-02-28 | 2045-03 | 2045-03 | 2025-01-10 | 2026-01-16 | Relapsed AML; Refractory AML | Leukemia, Myeloid, Acute; Recurrence; Leukemia | BIOLOGICAL; DRUG | CART123 Cells; Ruxolitinib 10 MG; Ruxolitinib 5 MG | ruxolitinib | University of Pennsylvania | OTHER | Novartis | false | United States | 1 | ALL | 18 Years | null | false | Evaluate the safety of CART123 cells when given in combination with ruxolitinib | 50424 | https://clinicaltrials.gov/study/NCT06768476 |
NCT03669276 | Effect of Gonadotropin Types and Indications on Homologous Intrauterine Insemination Success | GONADOTROP | COMPLETED | null | OBSERVATIONAL | null | null | null | null | 1,251 | ACTUAL | 2014-08-01 | 2017-11-21 | 2017-11-21 | 2018-09-13 | 2026-06-16 | Infertility | Infertility | null | null | null | Centre Hospitalier Universitaire, Amiens | OTHER | null | false | France | 1 | FEMALE | 20 Years | 44 Years | null | Success factors in the ovarian stimulation | PI2017_843_0046 | https://clinicaltrials.gov/study/NCT03669276 |
NCT04702776 | Study to Compare the Efficacy of the Ophthalmic Solution Humylub Ofteno® PF With Hyabak® and Lagricel Ofteno® PF as Treatment for Dry Eye. | PRO-087 | COMPLETED | null | INTERVENTIONAL | PHASE4 | RANDOMIZED | TREATMENT | DOUBLE | 182 | ACTUAL | 2021-12-09 | 2023-05-15 | 2023-05-15 | 2021-01-11 | 2026-02-20 | Dry Eye | Dry Eye Syndromes | DRUG | Sodium hyaluronate 0.1%/chondroitin sulfate 0.18%; Sodium hyaluronate 0.15%; Sodium hyaluronate 0.4% | Hyaluronic Acid | Laboratorios Sophia S.A de C.V. | INDUSTRY | null | true | Mexico | 1 | ALL | 18 Years | null | false | Change in Ocular Surface Disease Index (OSDI) | SOPH087-0120/IV | https://clinicaltrials.gov/study/NCT04702776 |
NCT03332017 | A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma | ROSEWOOD | COMPLETED | null | INTERVENTIONAL | PHASE2 | RANDOMIZED | TREATMENT | NONE | 217 | ACTUAL | 2017-11-14 | 2021-10-08 | 2024-12-27 | 2017-11-06 | 2026-02-18 | Relapsed/Refractory Follicular Non-Hodgkin Lymphoma | Lymphoma, Follicular | DRUG | Zanubrutinib; Obinutuzumab | zanubrutinib; obinutuzumab | BeiGene | INDUSTRY | null | true | United States; Australia; Belarus; Bulgaria; Canada; China; Czechia; France; Germany; Italy; New Zealand; Poland; Russia; South Korea; Spain; Taiwan; United Kingdom | 88 | ALL | 18 Years | null | false | Overall Response Rate (ORR) by Independent Central Review (ICR) Assessment | BGB-3111-212; 2017-001552-54; CTR20220712; 2023-509975-17-00; 2023; 2017 | https://clinicaltrials.gov/study/NCT03332017 |
NCT02942017 | A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C) | null | COMPLETED | null | INTERVENTIONAL | PHASE3 | RANDOMIZED | TREATMENT | QUADRUPLE | 108 | ACTUAL | 2016-07 | 2017-09-17 | 2017-10-11 | 2016-10-21 | 2025-09-15 | Postpartum Depression | Depression, Postpartum | DRUG | Placebo; SAGE-547 90 μg/kg/h | brexanolone | Supernus Pharmaceuticals, Inc. | INDUSTRY | null | true | United States | 32 | FEMALE | 18 Years | 45 Years | false | Change From Baseline at 60 Hours in 17-Item Hamilton Rating Scale for Depression (HAM-D) Total Score | 547-PPD-202 C | https://clinicaltrials.gov/study/NCT02942017 |
NCT00487617 | Arteriopathy and Endothelial Function | null | UNKNOWN | null | INTERVENTIONAL | NA | RANDOMIZED | TREATMENT | QUADRUPLE | 50 | ESTIMATED | 2007-07 | 2011-10 | 2012-04 | 2007-06-18 | 2009-02-25 | Peripheral Arterial Disease | Peripheral Arterial Disease | PROCEDURE | Fruit juice or placebo absorption | Fruit and Vegetable Juices | University Hospital, Strasbourg, France | OTHER | null | false | France | 2 | ALL | 18 Years | 70 Years | false | Endothelial function 1 hour after taking the juice | 3801 | https://clinicaltrials.gov/study/NCT00487617 |
NCT05618717 | Surpoint Algorithm for Improved Guidance of Ablation for Ventricular Tachycardia | SURFIRE-VT | COMPLETED | null | OBSERVATIONAL | null | null | null | null | 103 | ACTUAL | 2018-01-01 | 2022-11-11 | 2023-01-31 | 2022-11-16 | 2023-12-05 | Ventricular Tachycardia | Tachycardia, Ventricular | DEVICE | Radiofrequency Ablation | Radiofrequency Ablation | Rush University Medical Center | OTHER | null | false | United States | 1 | ALL | 19 Years | 80 Years | true | Recurrence Event of Sustained Ventricular Tachycardia or ICD therapy | 21011101 | https://clinicaltrials.gov/study/NCT05618717 |
NCT06076317 | Relevance of a Telemedicine Monitoring in the Management of Depression | TELEDEP | RECRUITING | null | INTERVENTIONAL | NA | RANDOMIZED | SUPPORTIVE_CARE | NONE | 836 | ESTIMATED | 2024-05-27 | 2026-08-02 | 2029-02-02 | 2023-10-10 | 2025-08-22 | Major Depressive Disorder | Depressive Disorder, Major | BEHAVIORAL | Telemedicine session | null | Assistance Publique - Hôpitaux de Paris | OTHER | null | false | France | 1 | ALL | 18 Years | null | false | Treatment response rate at 6 months after inclusion. | APHP210990; 2023-A00119-36 | https://clinicaltrials.gov/study/NCT06076317 |
End of preview. Expand in Data Studio
Trialtide: every ClinicalTrials.gov study in one table
Need it fresh, filtered or via API? This free file is a snapshot (the ClinicalTrials.gov registry at the last refresh), last updated 2026-09-24.
- Swellmeter on Apify ($0.003 per keyword analyzed): checks Google Trends direction for your own keywords with a plain rising/falling verdict, daily if scheduled.
- Get an email when this dataset updates: free, double opt-in, unsubscribe any time.
Information only, not medical advice.
All 604,146 studies registered on ClinicalTrials.gov, flattened to one row per study: status, phase, design, enrollment, key dates, conditions (with MeSH terms), interventions, lead sponsor and sponsor type, collaborators, countries, number of sites, eligibility basics, primary outcomes and whether results are posted.
Data processed by ClinicalTrials.gov: 2026-09-23T09:00:05 (the API's dataTimestamp); this copy was built 2026-09-24T01:49:51Z (see meta.json).
In this build: 461,069 interventional and 141,027 observational studies; 64,984 recruiting now; 80,203 with results posted; by lead sponsor type, 132,535 industry, 11,576 NIH and 4,937 other US federal.
One Parquet file (~140 MB), no API paging, no nested JSON: pipeline tracking, competitive intelligence, trial-site research, RAG over trial metadata, or training classifiers.
Use it
from datasets import load_dataset
df = load_dataset("CyberMax-tools/trialtide-clinicaltrials-registry", split="train").to_pandas()
# Industry phase 3 trials recruiting now for a condition
p3 = df[(df.overall_status == "RECRUITING") & df.phases.str.contains("PHASE3", na=False)
& (df.lead_sponsor_class == "INDUSTRY") & df.conditions.str.contains("obesity", case=False, na=False)]
print(p3[["nct_id", "brief_title", "lead_sponsor", "enrollment", "primary_completion_date"]])
# Why do trials stop?
print(df.why_stopped_category.value_counts())
DuckDB: SELECT lead_sponsor, count(*) FROM 'hf://datasets/CyberMax-tools/trialtide-clinicaltrials-registry/data/studies.parquet' WHERE overall_status='RECRUITING' AND lead_sponsor_class='INDUSTRY' GROUP BY 1 ORDER BY 2 DESC LIMIT 20.
Columns
nct_id, brief_title, acronym, overall_status (RECRUITING, COMPLETED, TERMINATED...), why_stopped_category, study_type (INTERVENTIONAL, OBSERVATIONAL, EXPANDED_ACCESS), phases (;-separated, e.g. PHASE2; PHASE3), allocation, primary_purpose, masking, enrollment, enrollment_type (ACTUAL or ESTIMATED), start_date, primary_completion_date, completion_date, first_posted, last_updated, conditions, condition_mesh_terms, intervention_types, interventions (first 30), intervention_mesh_terms, lead_sponsor, lead_sponsor_class (INDUSTRY, NIH, FED, OTHER_GOV, NETWORK, OTHER, INDIV...), collaborators (first 20), has_results, countries, site_count, sex, minimum_age, maximum_age, healthy_volunteers, primary_outcomes (first 10 measures), secondary_ids (the sponsor's own study IDs and registry cross-references), url.
Dates are as registered: YYYY-MM-DD or YYYY-MM when the registry gives only a month. Lists are ; -separated strings.
Changes from the source (as the ClinicalTrials.gov terms ask)
- Flattened from the API v2 JSON to one row per study; only the fields above are kept.
- Privacy: no contacts, investigators, study officials, site names or addresses, and no free-text eligibility criteria. Sponsors and collaborators that are, or may be, individual people are left blank: every sponsor of class
INDIV, and names of classOTHER/UNKNOWN/AMBIGthat aren't clearly an organisation (sponsor-investigators often register under their own name), and any name carrying an academic degree (MD, PhD…) or a personal title with an affiliation ("Dr. X, Some University"). Institutions named after people ("Hospital Dr. Sotero del Rio") are kept. The class column is kept. The free-text reason a study stopped often names people, so onlywhy_stopped_categoryis published: a keyword category (low_enrollment,funding,business_decision,safety,efficacy_or_futility,covid19,investigator_or_site,regulatory_or_ethics,drug_supply,study_design_or_logistics,never_started,other) assigned by CyberMax, not by the registry. - Duplicate list entries removed; long lists capped as noted above.
Licence and attribution
Source: ClinicalTrials.gov, a service of the US National Library of Medicine (NIH). The data is in the US public domain. As its terms request: the source is ClinicalTrials.gov, the processing date is shown above and in meta.json, and all changes are listed in the section above. The copy is refreshed regularly so it stays current. Neither the US Government, HHS, NIH nor NLM makes any warranty about the data or endorses this dataset.
Compiled by CyberMax. Not medical advice. To find a trial for yourself, use ClinicalTrials.gov and talk to your doctor.
Also from CyberMax
- Free datasets: Kevscope: CVE + CISA KEV + EPSS · Eventwren: SEC 8-K events by Item
- Tools for AI agents and data teams (pay per use, on Apify): https://apify.com/cybermax
More free from CyberMax
- Downloads last month
- 10